Therapy targeting immune checkpoints represents an integral part of the treatment for patients suffering from advanced melanoma. However, the mechanisms of resistance are responsible for a lower therapeutic outcome than expected. Concerning melanoma, insufficient stimulation of the immune system by tumour neoantigens is a likely explanation. As shown previously, radiotherapy is a known option for increasing the production of tumour neoantigens and their release into the microenvironment. Consequently, neoantigens could be recognized by antigen presenting cells (APCs) and subjected to effector T lymphocytes. Enhancing the immune reaction can trigger the therapeutic response also at distant metastases, a phenomenon known as an abscopal effect (from "ab scopus", that is, away from the target). To illustrate this, we present the case of a 78-year old male treated by anti-CTLA-4/ipilimumab for metastatic melanoma. The patient received the standard four doses of ipilimumab administered every three weeks. However, the control CT scans detected disease progression in the form of axillary lymph nodes metastasis and liver metastasis two months after ipilimumab. At this stage, palliative cryotherapy of the skin metastases was initiated to alleviate the tumour burden. Surprisingly, the effect of cryotherapy was also observed in untreated metastases and deep subcutaneous metastases on the back. Moreover, we observed the disease remission of axillary lymph nodes and liver metastasis two months after the cryotherapy. The rarity of the abscopal effect suggests that even primed anti-tumour CD8+ T cells cannot overcome the tumour microenvironment's suppressive effect and execute immune clearance. However, the biological mechanism underlying this phenomenon is yet to be elucidated. The elicitation of a systemic response by cryotherapy with documented abscopal effect was rarely reported, although the immune response induction is presumably similar to a radiotherapy-induced one. The report is a combination case study and review of the abscopal effect in melanoma treated with checkpoint inhibitors.

Biotechnology and Biomedicine Center Academy of Science and Charles University 252 50 Vestec Czech Republic

Department of Dermatovenereology 1st Faculty of Medicine and General University Hospital Charles University 128 00 Prague Czech Republic

Institute of Anatomy 1st Faculty of Medicine Charles University 128 00 Prague Czech Republic

Institute of Pathology 1st Faculty of Medicine and General University Hospital Charles University 128 00 Prague Czech Republic

Zobrazit více v PubMed

Hodi F.S., O’Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N. Engl. J. Med. 2010;363:711–723. doi: 10.1056/NEJMoa1003466. PubMed DOI PMC

Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Rutkowski P., Lao C.D., Cowey C.L., Schadendorf D., Wagstaff J., Dummer R., et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2019;381:1535–1546. doi: 10.1056/NEJMoa1910836. PubMed DOI

Jiang T., Shi T., Zhang H., Hu J., Song Y., Wei J., Ren S., Zhou C. Tumor Neoantigens: From Basic Research to Clinical Applications. J. Hematol. Oncol. 2019;12:1–13. doi: 10.1186/s13045-019-0787-5. PubMed DOI PMC

Huang J., El-Gamil M., Dudley M.E., Li Y.F., Rosenberg S.A., Robbins P.F. T Cells Associated with Tumor Regression Recognize Frameshifted Products of the CDKN2A Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product. J. Immunol. 2004;172:6057–6064. doi: 10.4049/jimmunol.172.10.6057. PubMed DOI PMC

Bonaventura P., Shekarian T., Alcazer V., Valladeau-Guilemond J., Valsesia-Wittmann S., Amigorena S., Caux C., Depil S. Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front. Immunol. 2019;10:168. doi: 10.3389/fimmu.2019.00168. PubMed DOI PMC

Nowicki T.S., Hu-Lieskovan S., Ribas A. Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J. 2018;24:47–53. doi: 10.1097/PPO.0000000000000303. PubMed DOI PMC

Hugo W., Zaretsky J.M., Sun L., Song C., Moreno B.H., Hu-Lieskovan S., Berent-Maoz B., Pang J., Chmielowski B., Cherry G., et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016;165:35–44. doi: 10.1016/j.cell.2016.02.065. PubMed DOI PMC

Ayers M., Lunceford J., Nebozhyn M., Murphy E., Loboda A., Kaufman D.R., Albright A., Cheng J.D., Kang S.P., Shankaran V., et al. IFN-γ-Related MRNA Profile Predicts Clinical Response to PD-1 Blockade. J. Clin. Investig. 2017;127:2930–2940. doi: 10.1172/JCI91190. PubMed DOI PMC

Vilain R.E., Menzies A.M., Wilmott J.S., Kakavand H., Madore J., Guminski A., Liniker E., Kong B.Y., Cooper A.J., Howle J.R., et al. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early during Treatment Predict Response to PD-1 Blockade in Melanoma. Clin. Cancer Res. 2017;23:5024–5033. doi: 10.1158/1078-0432.CCR-16-0698. PubMed DOI

Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., Walsh L.A., Postow M.A., Wong P., Ho T.S., et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. N. Engl. J. Med. 2014;371:2189–2199. doi: 10.1056/NEJMoa1406498. PubMed DOI PMC

Gao J., Shi L.Z., Zhao H., Chen J., Xiong L., He Q., Chen T., Roszik J., Bernatchez C., Woodman S.E., et al. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016;167:397–404. doi: 10.1016/j.cell.2016.08.069. PubMed DOI PMC

McGranahan N., Furness A.J.S., Rosenthal R., Ramskov S., Lyngaa R., Saini S.K., Jamal-Hanjani M., Wilson G.A., Birkbak N.J., Hiley C.T., et al. Clonal Neoantigens Elicit T Cell Immunoreactivity and Sensitivity to Immune Checkpoint Blockade. Science. 2016;351:1463–1469. doi: 10.1126/science.aaf1490. PubMed DOI PMC

Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., et al. Patterns of Somatic Mutation in Human Cancer Genomes. Nature. 2007;446:153–158. doi: 10.1038/nature05610. PubMed DOI PMC

Gros A., Parkhurst M.R., Tran E., Pasetto A., Robbins P.F., Ilyas S., Prickett T.D., Gartner J.J., Crystal J.S., Roberts I.M., et al. Prospective Identification of Neoantigen-Specific Lymphocytes in the Peripheral Blood of Melanoma Patients. Nat. Med. 2016;22:433–438. doi: 10.1038/nm.4051. PubMed DOI PMC

Zhao X., Shao C. Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade. Cancers. 2020;12:2762. doi: 10.3390/cancers12102762. PubMed DOI PMC

MOLE R.H. Whole Body Irradiation; Radiobiology or Medicine? Br. J. Radiol. 1953;26:234–241. doi: 10.1259/0007-1285-26-305-234. PubMed DOI

Golden E.B., Demaria S., Schiff P.B., Chachoua A., Formenti S.C. An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer. Cancer Immunol. Res. 2013;1:365–372. doi: 10.1158/2326-6066.CIR-13-0115. PubMed DOI PMC

Liu Y., Dong Y., Kong L., Shi F., Zhu H., Yu J. Abscopal Effect of Radiotherapy Combined with Immune Checkpoint Inhibitors. J. Hematol. Oncol. 2018;11:1–15. doi: 10.1186/s13045-018-0647-8. PubMed DOI PMC

Chandra R.A., Wilhite T.J., Balboni T.A., Alexander B.M., Spektor A., Ott P.A., Ng A.K., Hodi F.S., Schoenfeld J.D. A Systematic Evaluation of Abscopal Responses Following Radiotherapy in Patients with Metastatic Melanoma Treated with Ipilimumab. Oncoimmunology. 2015;4:1–7. doi: 10.1080/2162402X.2015.1046028. PubMed DOI PMC

Mukhopadhyay A., Wright J., Shirley S., Canton D.A., Burkart C., Connolly R.J., Campbell J.S., Pierce R.H. Characterization of Abscopal Effects of Intratumoral Electroporation-Mediated IL-12 Gene Therapy. Gene Ther. 2019;26:1–15. doi: 10.1038/s41434-018-0044-5. PubMed DOI PMC

Iwai T., Oebisu N., Hoshi M., Orita K., Yamamoto A., Hamamoto S., Kageyama K., Nakamura H. Promising Abscopal Effect of Combination Therapy with Thermal Tumour Ablation and Intratumoural OK-432 Injection in the Rat Osteosarcoma Model. Sci. Rep. 2020;10:9679. doi: 10.1038/s41598-020-66934-6. PubMed DOI PMC

Abdo J., Cornell D.L., Mittal S.K., Agrawal D.K. Immunotherapy plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers. Front. Oncol. 2018;8:85. doi: 10.3389/fonc.2018.00085. PubMed DOI PMC

Tel J., Anguille S., Waterborg C.E.J., Smits E.L., Figdor C.G., de Vries I.J.M. Tumoricidal Activity of Human Dendritic Cells. Trends Immunol. 2014;35:38–46. doi: 10.1016/j.it.2013.10.007. PubMed DOI PMC

Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., et al. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. N. Engl. J. Med. 2012;366:883–892. doi: 10.1056/NEJMoa1113205. PubMed DOI PMC

Mukherji B. Immunology of Melanoma. Clin. Dermatol. 2013;31:156–165. doi: 10.1016/j.clindermatol.2012.08.017. PubMed DOI

Lee Y., Auh S.L., Wang Y., Burnette B., Wang Y., Meng Y., Beckett M., Sharma R., Chin R., Tu T., et al. Therapeutic Effects of Ablative Radiation on Local Tumor Require CD8 + T Cells: Changing Strategies for Cancer Treatment. Blood. 2009;114:589–595. doi: 10.1182/blood-2009-02-206870. PubMed DOI PMC

Demaria S., Ng B., Devitt M.L., Babb J.S., Kawashima N., Liebes L., Formenti S.C. Ionizing Radiation Inhibition of Distant Untreated Tumors (Abscopal Effect) Is Immune Mediated. Int. J. Radiat. Oncol. Biol. Phys. 2004;58:862–870. doi: 10.1016/j.ijrobp.2003.09.012. PubMed DOI

Ribas A., Dummer R., Puzanov I., VanderWalde A., Andtbacka R.H.I., Michielin O., Olszanski A.J., Malvehy J., Cebon J., Fernandez E., et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170:1109–1119.e10. doi: 10.1016/j.cell.2017.08.027. PubMed DOI PMC

Marchini A., Daeffler L., Pozdeev V.I., Angelova A., Rommelaere J. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. Front. Immunol. 2019;10:1848. doi: 10.3389/fimmu.2019.01848. PubMed DOI PMC

Capone M., Giannarelli D., Mallardo D., Madonna G., Festino L., Grimaldi A.M., Vanella V., Simeone E., Paone M., Palmieri G., et al. Baseline Neutrophil-to-Lymphocyte Ratio (NLR) and Derived NLR Could Predict Overall Survival in Patients with Advanced Melanoma Treated with Nivolumab. J. Immunother. Cancer. 2018;6:1–7. doi: 10.1186/s40425-018-0383-1. PubMed DOI PMC

Robert C., Thomas L., Bondarenko I., O’Day S., Weber J., Garbe C., Lebbe C., Baurain J.-F., Testori A., Grob J.-J., et al. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N. Engl. J. Med. 2011;364:2517–2526. doi: 10.1056/NEJMoa1104621. PubMed DOI

Schadendorf D., Hodi F.S., Robert C., Weber J.S., Margolin K., Hamid O., Patt D., Chen T.T., Berman D.M., Wolchok J.D. Pooled Analysis of Long-Term Survival Data from Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J. Clin. Oncol. 2015;33:1889–1894. doi: 10.1200/JCO.2014.56.2736. PubMed DOI PMC

Grimaldi A.M., Simeone E., Giannarelli D., Muto P., Falivene S., Borzillo V., Giugliano F.M., Sandomenico F., Petrillo A., Curvietto M., et al. Abscopal Effects of Radiotherapy on Advanced Melanoma Patients Who Progressed after Ipilimumab Immunotherapy. Oncoimmunology. 2014;3:e28780. doi: 10.4161/onci.28780. PubMed DOI PMC

Liang H., Deng L., Chmura S., Burnette B., Liadis N., Darga T., Beckett M.A., Lingen M.W., Witt M., Weichselbaum R.R., et al. Radiation-Induced Equilibrium Is a Balance between Tumor Cell Proliferation and T Cell–Mediated Killing. J. Immunol. 2013;190:5874–5881. doi: 10.4049/jimmunol.1202612. PubMed DOI PMC

Park S.S., Dong H., Liu X., Harrington S.M., Krco C.J., Grams M.P., Mansfield A.S., Furutani K.M., Olivier K.R., Kwon E.D. PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer Immunol. Res. 2015;3:610–619. doi: 10.1158/2326-6066.CIR-14-0138. PubMed DOI PMC

Pilones K.A., Kawashima N., Yang A.M., Babb J.S., Formenti S.C., Demaria S. Invariant Natural Killer T Cells Regulate Breast Cancer Response to Radiation and CTLA-4 Blockade. Clin. Cancer Res. 2009;15:597–606. doi: 10.1158/1078-0432.CCR-08-1277. PubMed DOI PMC

Milano M.T., Katz A.W., Zhang H., Okunieff P. Oligometastases Treated with Stereotactic Body Radiotherapy: Long-Term Follow-up of Prospective Study. Int. J. Radiat. Oncol. Biol. Phys. 2012;83:878–886. doi: 10.1016/j.ijrobp.2011.08.036. PubMed DOI

Salama J.K., Hasselle M.D., Chmura S.J., Malik R., Mehta N., Yenice K.M., Villaflor V.M., Stadler W.M., Hoffman P.C., Cohen E.E.W., et al. Stereotactic Body Radiotherapy for Multisite Extracranial Oligometastases: Final Report of a Dose Escalation Trial in Patients with 1 to 5 Sites of Metastatic Disease. Cancer. 2012;118:2962–2970. doi: 10.1002/cncr.26611. PubMed DOI

Schreiber R.D., Old L.J., Smyth M.J. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion. Science. 2011;331:1565–1570. doi: 10.1126/science.1203486. PubMed DOI

Zhang D., Bi J., Liang Q., Wang S., Zhang L., Han F., Li S., Qiu B., Fan X., Chen W., et al. VCAM1 Promotes Tumor Cell Invasion and Metastasis by Inducing EMT and Transendothelial Migration in Colorectal Cancer. Front. Oncol. 2020;10:1066. doi: 10.3389/fonc.2020.01066. PubMed DOI PMC

Johnson J.P. Cell Adhesion Molecules in the Development and Progression of Malignant Melanoma. Cancer Metastasis Rev. 1999;18:345–357. doi: 10.1023/A:1006304806799. PubMed DOI

Reits E.A., Hodge J.W., Herberts C.A., Groothuis T.A., Chakraborty M., Wansley E.K., Camphausen K., Luiten R.M., De Ru A.H., Neijssen J., et al. Radiation Modulates the Peptide Repertoire, Enhances MHC Class I Expression, and Induces Successful Antitumor Immunotherapy. J. Exp. Med. 2006;203:1259–1271. doi: 10.1084/jem.20052494. PubMed DOI PMC

Chakraborty M., Abrams S.I., Camphausen K., Liu K., Scott T., Coleman C.N., Hodge J.W. Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy. J. Immunol. 2003;170:6338–6347. doi: 10.4049/jimmunol.170.12.6338. PubMed DOI

Fuertes M.B., Kacha A.K., Kline J., Woo S.R., Kranz D.M., Murphy K.M., Gajewski T.F. Host Type I IFN Signals Are Required for Antitumor CD8+ T Cell Responses through CD8α+ Dendritic Cells. J. Exp. Med. 2011;208:2005–2016. doi: 10.1084/jem.20101159. PubMed DOI PMC

Grasso C.S., Tsoi J., Onyshchenko M., Abril-Rodriguez G., Ross-Macdonald P., Wind-Rotolo M., Champhekar A., Medina E., Torrejon D.Y., Shin D.S., et al. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2020;38:500–515.e3. doi: 10.1016/j.ccell.2020.08.005. PubMed DOI PMC

Zhou J., Wang G., Chen Y., Wang H., Hua Y., Cai Z. Immunogenic Cell Death in Cancer Therapy: Present and Emerging Inducers. J. Cell. Mol. Med. 2019;23:4854–4865. doi: 10.1111/jcmm.14356. PubMed DOI PMC

Gardai S.J., McPhillips K.A., Frasch S.C., Janssen W.J., Starefeldt A., Murphy-Ullrich J.E., Bratton D.L., Oldenborg P.A., Michalak M., Henson P.M. Cell-Surface Calreticulin Initiates Clearance of Viable or Apoptotic Cells through Trans-Activation of LRP on the Phagocyte. Cell. 2005;123:321–334. doi: 10.1016/j.cell.2005.08.032. PubMed DOI

Perregaux D.G., McNiff P., Laliberte R., Conklyn M., Gabel C.A. ATP Acts as an Agonist to Promote Stimulus-Induced Secretion of IL-1β and IL-18 in Human Blood. J. Immunol. 2000;165:4615–4623. doi: 10.4049/jimmunol.165.8.4615. PubMed DOI

Vijay K. Toll-like Receptors in Immunity and Inflammatory Diseases: Past, Present, and Future. Int. Immunopharmacol. 2018;59:391–412. doi: 10.1016/j.intimp.2018.03.002. PubMed DOI PMC

Herrera F.G., Bourhis J., Coukos G. Radiotherapy Combination Opportunities Leveraging Immunity for the next Oncology Practice. CA. Cancer J. Clin. 2017;67:65–85. doi: 10.3322/caac.21358. PubMed DOI

Pedicord V.A., Montalvo W., Leiner I.M., Allison J.P. Single Dose of Anti-CTLA-4 Enhances CD8+ T-Cell Memory Formation, Function, and Maintenance. Proc. Natl. Acad. Sci. USA. 2011;108:266–271. doi: 10.1073/pnas.1016791108. PubMed DOI PMC

Herbst R.S., Baas P., Kim D.W., Felip E., Pérez-Gracia J.L., Han J.Y., Molina J., Kim J.H., Arvis C.D., Ahn M.J., et al. Pembrolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. Lancet. 2016;387:1540–1550. doi: 10.1016/S0140-6736(15)01281-7. PubMed DOI

Long G.V., Larkin J., Ascierto P.A., Hodi F.S., Rutkowski P., Sileni V., Hassel J., Lebbe C., Pavlick A.C., Wagstaff J., et al. Melanoma and Other Skin Tumours 1112PD PD-L1 Expression as a Biomarker for Nivolumab (NIVO) plus Ipilimumab (IPI) and NIVO Alone in Advanced Melanoma (MEL): A Pooled Analysis. Ann. Oncol. 2016;27:379–400. doi: 10.1093/annonc/mdw379.07. PubMed DOI

Deng L., Liang H., Burnette B., Beckett M., Darga T., Weichselbaum R.R., Fu Y.X. Irradiation and Anti-PD-L1 Treatment Synergistically Promote Antitumor Immunity in Mice. J. Clin. Investig. 2014;124:687–695. doi: 10.1172/JCI67313. PubMed DOI PMC

Tsui J.M., Mihalcioiu C., Cury F.L. Abscopal Effect in a Stage IV Melanoma Patient Who Progressed on Pembrolizumab. Cureus. 2018;10:e2238. doi: 10.7759/cureus.2238. PubMed DOI PMC

Tchanque-Fossuo C.N., Eisen D.B. A Systematic Review on the Use of Cryotherapy versus Other Treatments for Basal Cell Carcinoma. Dermatol. Online J. 2018;24 doi: 10.1016/j.jid.2017.02.389. PubMed DOI

Zeng Y., Hu C., Shu L., Pan Y., Zhao L., Pu X., Wu F. Clinical Treatment Options for Early-Stage and Advanced Conjunctival Melanoma. Surv. Ophthalmol. 2020;66:461–470. doi: 10.1016/j.survophthal.2020.09.004. PubMed DOI

John H.E., Mahaffey P.J. Laser Ablation and Cryotherapy of Melanoma Metastases. J. Surg. Oncol. 2014;109:296–300. doi: 10.1002/jso.23488. PubMed DOI

Bala M.M., Riemsma R.P., Wolff R., Kleijnen J. Cryotherapy for Liver Metastases. Cochrane Database Syst. Rev. 2013:CD009058. doi: 10.1002/14651858.CD009058.pub2. PubMed DOI

Slovak R., Ludwig J.M., Gettinger S.N., Herbst R.S., Kim H.S. Immuno-Thermal Ablations–Boosting the Anticancer Immune Response. J. Immunother. Cancer. 2017;5:1–15. doi: 10.1186/s40425-017-0284-8. PubMed DOI PMC

Gazzaniga S., Bravo A., Goldszmid S.R., Maschi F., Martinelli J., Mordoh J., Wainstok R. Inflammatory Changes after Cryosurgery-Induced Necrosis in Human Melanoma Xenografted in Nude Mice. J. Investig. Dermatol. 2001;116:664–671. doi: 10.1046/j.0022-202x.2001.01313.x. PubMed DOI

Liu Y.C., Zou X.B., Chai Y.F., Yao Y.M. Macrophage Polarization in Inflammatory Diseases. Int. J. Biol. Sci. 2014;10:520–529. doi: 10.7150/ijbs.8879. PubMed DOI PMC

Zhou J., Tang Z., Gao S., Li C., Feng Y., Zhou X. Tumor-Associated Macrophages: Recent Insights and Therapies. Front. Oncol. 2020;10:188. doi: 10.3389/fonc.2020.00188. PubMed DOI PMC

Gu Y., Srimathveeravalli G., Cai L., Ueshima E., Maybody M., Yarmohammadi H., Zhu Y.S., Durack J.C., Solomon S.B., Coleman J.A., et al. Pirfenidone Inhibits Cryoablation Induced Local Macrophage Infiltration along with Its Associated TGFb1 Expression and Serum Cytokine Level in a Mouse Model. Cryobiology. 2018;82:106–111. doi: 10.1016/j.cryobiol.2018.03.012. PubMed DOI PMC

Takahashi Y., Izumi Y., Matsutani N., Dejima H., Nakayama T., Okamura R., Uehara H., Kawamura M. Optimized Magnitude of Cryosurgery Facilitating Anti-Tumor Immunoreaction in a Mouse Model of Lewis Lung Cancer. Cancer Immunol. Immunother. 2016;65:973–982. doi: 10.1007/s00262-016-1858-x. PubMed DOI PMC

Den Brok M.H.M.G.M., Sutmuller R.P.M., Nierkens S., Bennink E.J., Toonen L.W.J., Figdor C.G., Ruers T.J.M., Adema G.J. Synergy between in Situ Cryoablation and TLR9 Stimulation Results in a Highly Effective in Vivo Dendritic Cell Vaccine. Cancer Res. 2006;66:7285–7292. doi: 10.1158/0008-5472.CAN-06-0206. PubMed DOI

Lacina L., Kodet O., Dvořánková B., Szabo P., Smetana K. Ecology of Melanoma Cell. Histol. Histopathol. 2018;33:247–254. PubMed

Dvorak H.F. Tumors: Wounds That Do Not Heal-Redux. Cancer Immunol. Res. 2015;3:1–11. doi: 10.1158/2326-6066.CIR-14-0209. PubMed DOI PMC

Jobe N.P., Živicová V., Mifková A., Rösel D., Dvořánková B., Kodet O., Strnad H., Kolář M., Šedo A., Smetana K., et al. Fibroblasts Potentiate Melanoma Cells in Vitro Invasiveness Induced by UV-Irradiated Keratinocytes. Histochem. Cell Biol. 2018;149:503–516. doi: 10.1007/s00418-018-1650-4. PubMed DOI

Čoma M., Fröhlichová L., Urban L., Zajícĕk R., Urban T., Szabo P., Novák Š., Fetissov V., Dvořánková B., Smetana K., et al. Molecular Changes Underlying Hypertrophic Scarring Following Burns Involve Specific Deregulations at Allwound Healing Stages (Inflammation, Proliferation and Maturation) Int. J. Mol. Sci. 2021;22:897. doi: 10.3390/ijms22020897. PubMed DOI PMC

Ressler J.M., Karasek M., Koch L., Silmbrod R., Mangana J., Latifyan S., Aedo-Lopez V., Kehrer H., Weihsengruber F., Koelblinger P., et al. Real-Life Use of Talimogene Laherparepvec (T-VEC) in Melanoma Patients in Centers in Austria, Switzerland and Germany. J. Immunother. Cancer. 2021;9:e001701. doi: 10.1136/jitc-2020-001701. PubMed DOI PMC

Kepp O., Marabelle A., Zitvogel L., Kroemer G. Oncolysis without Viruses–Inducing Systemic Anticancer Immune Responses with Local Therapies. Nat. Rev. Clin. Oncol. 2020;17:49–64. doi: 10.1038/s41571-019-0272-7. PubMed DOI